pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·4h ago·1 min read
save

ADA chief scientific officer Rita Kalyani departs amid ongoing review of New Orleans incident

Oct 21, 2026·read at STAT ↗Negative

The American Diabetes Association announced Tuesday that its chief scientific and medical officer, Dr. Rita Kalyani, is no longer in her role, effective immediately.

The move comes as the ADA continues a review of a June 5 incident at its New Orleans meeting, where five members were removed by armed security after distributing an editorial in Diabetes Care that warned about federal research funding cuts.

The organization has not provided an explanation for Dr. Kalyani’s departure, and the review of the June incident is expected to take additional time.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Another diabetes association leader is out while review continues”

read at STAT ↗
440 words · retrieved 4h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING2Ultragenyx Pharmaceutical Inc.
drugs
Rare Diseaseketamine
topics
Type 2 Diabetes8Cardiology4Endocrinology & Metabolism2ApprovalImmunologyOphthalmologyRare Disease

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AFierce Biotech
  • 11h agoPfizer trims manufacturing workforceBioSpace
  • Jul 24Amgen deploys patients to defend troubled Tavneos in FDA hearing requestBioSpace
  • Sep 24Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugsFierce Biotech